Correspondence

Eligibility for co-trimoxazole prophylaxis among adult HIV-infected patients in South Africa

Bookmark and Share
S Takuva, J M Nabyoma, H Dawood, A Black, G Maartens, A Parrish, T D Leong

Abstract


-

Authors' affiliations

S Takuva, Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg; and School of Health Systems and Public Health, Faculty of Health Sciences, University of Pretoria, South Africa

J M Nabyoma, Department of Pharmacy, Lehurutshe Hospital, North West Province Department of Health, Zeerust, South Africa

H Dawood, Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban; and Department of Internal Medicine, Grey’s Hospital, Pietermaritzburg, South Africa

A Black, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

G Maartens, Division of Clinical Pharmacology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, South Africa

A Parrish, Department of Medicine, Faculty of Health Sciences, Walter Sisulu University, Mthatha; and Department of Internal Medicine, Frere and Cecilia Makiwane hospitals, East London, South Africa

T D Leong, Essential Drugs Programme, National Department of Health, Pretoria, South Africa

Full Text

PDF (90KB)

Keywords

Co-trimoxazole; Prophylaxis; Adults; HIV-infected; South Africa

Cite this article

South African Medical Journal 2019;109(4):198-199. DOI:10.7196/SAMJ.2019.v109i4.13877

Article History

Date submitted: 2019-03-29
Date published: 2019-03-29

Article Views

Abstract views: 2729
Full text views: 1354

Comments on this article

*Read our policy for posting comments here